Thus, a treatment with the monoclonal antibody infliximab, an TNF-α antagonist, resulted in a greater reduction of depressive symptoms in a subset of medication resistant MDD patients with high baseline CRP levels (29). This evidence concerns the gene TNF and major depressive disorder.